dactinomycin / Generic mfg. - LARVOL DELTA

Congenital mesoblastic nephroma: a single-center retrospective study. (PubMed, Transl Pediatr) - "Two relapsed patients received salvage chemotherapy [vincristine-actinomycin D-cyclophosphamide (VAC) or ifosfamide-carboplatin-etoposide (ICE)], which showed limited efficacy. One relapsed patient with TPM3::NTRK1 received larotrectinib but died two months later; another with EGFR-KDD experienced disease stabilization after afatinib plus programmed cell death protein 1 (PD-1) blockade following progression on entrectinib and anlotinib...While most patients experienced favorable outcomes following surgery, relapsed cases highlight the challenges associated with molecularly atypical disease. These observations are descriptive in nature and underscore the need for larger collaborative studies to better define prognostic factors and optimal management strategies in CMN."

IO biomarker • Journal • Retrospective data • Kidney Cancer • Oncology • Pediatrics • Renal Cell Carcinoma • Solid Tumor • EGFR • ETV6 • NTRK1 • NTRK3 • TPM3

Knockdown of circFOXN3 Promotes the Proliferation and Differentiation of Bovine Myoblasts. (PubMed, Probiotics Antimicrob Proteins) - "We first confirmed the circular nature of circFOXN3 by identifying its specific back-splice junction via divergent primers and Sanger sequencing, and its resistance to RNase R digestion as well as stability under actinomycin D treatment were confirmed...Its silencing promotes myoblast expansion and terminal differentiation, likely by modulating key cell cycle pathways and gene expression networks via its cytoplasmic localization. These results position circFOXN3 as a promising molecular target for genetic strategies aimed at improving muscle growth and efficiency in cattle production."

Journal • BUB1 • CCNA2 • CCND2 • CDC20 • CDK1 • MYOD1 • Myogenin • PCNA

Maxillary mesenchymal chondrosarcoma harboring HEY1::NCOA2 fusion in a 13-year-old girl: a rare case report and literature review. (PubMed, Front Pediatr) - "The patient was treated with VAC chemotherapy (vincristine, actinomycin D, cyclophosphamide), local radiotherapy (60 Gy), cranial prophylactic radiotherapy (12 Gy), and subsequent debulking surgery. Multimodal treatment incorporating chemotherapy, radiotherapy, surgery, and targeted maintenance therapy can achieve meaningful disease control in aggressive craniofacial MCS. To our knowledge, this represents one of the very few reported pediatric cases of maxillary MCS with confirmed HEY1::NCOA2 fusion managed with sirolimus-based maintenance therapy."

Journal • Fibrosarcoma • Maxillary Sinus Carcinoma • Oncology • Pediatrics • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • CD34 • ETV6 • HEY1 • NCOA2 • NTRK3 • VIM

ZFP36 and CEBPA are macrophage-associated prognostic biomarkers linked to glomerular endothelial inflammation in ANCA-associated glomerulonephritis. (PubMed, Exp Cell Res) - "ZFP36 and CEBPA are macrophage-associated genes linked to immune infiltration, renal prognosis, and endothelial inflammatory responses in AAGN, and may serve as potential tissue biomarkers and therapeutic targets."

Biomarker • Journal • Glomerulonephritis • Inflammation • Lupus Nephritis • Nephrology • Vasculitis • CD31 • CEBPA • IL6 • PECAM1 • TNFA • ZFP36

Gene transcription and mRNA translation requirements for long-term excitability changes induced by aversive experience in the feeding neural circuit of Aplysia. (PubMed, Neurosci Lett) - "Results indicate that actinomycin D and anisomycin blocked the expression of both forms of plasticity. These findings demonstrate that concurrent experience-dependent long-term cellular changes in defensive and appetitive circuits share the same transcription and translation requirements to ensure persistence over time."

Journal

METTL3-mediated TIGAR m6A modification and its role in microglia activation related to Alzheimer's disease. (PubMed, Neuroreport) - "METTL3 modulates the balance of Aβ-induced polarization and microglia activation in HMC3 cells by upregulating TIGAR, promoting polarization toward an anti-inflammatory profile."

Journal • Alzheimer's Disease • CNS Disorders • CD86 • IL10 • IL1B • METTL3 • MRC1 • TIGAR

Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor. (PubMed, Cell Rep) - "We induce a patient-derived xenograft model (KT-47) to develop blastemal predominance after chemotherapy and to become resistant to vincristine, actinomycin-D, and doxorubicin (VAD). These findings are validated in additional Wilms tumor models. Overall, resistance is associated with de-differentiation to a stem-like state and is driven by ABCB1 upregulation, suggesting that therapeutic strategies targeting chromatin regulation and drug efflux may be relevant in therapy-resistant Wilms tumor."

Journal • Nephrology • Oncology • Solid Tumor • Wilms Tumor • ABCB1 • LIN28B • MYCN

Virtual effect-directed analysis of granulated rubber identifies bioactive chemicals and distinct hazard profiles. (PubMed, J Hazard Mater) - "Of 21 samples, all except one showed aryl-hydrocarbon receptor (AhR) activity (14-31,400 ng benzo[a]pyrene equivalents/g), four induced p53 activity (0.04-0.86 µg actinomycin D equivalents/g) and two showed estrogen receptor α (ERα) activity (530 and 1020 pg estradiol equivalents/g)...Styrene-butadiene rubber (SBR) showed higher AhR- and p53 activities and concentrations of quantified compounds than the alternative materials. The study highlights differences in chemical hazards among rubber infill materials and demonstrates the utility of vEDA as an early-warning tool for identifying compounds of concern."

Journal • ER

Analysis of 1000 secreted proteins in functional genomics and compound screens reveals cytotoxic and immunomodulatory targets (AACR 2026) - "Actinomycin D was cytotoxic while inducing IL-1b and TNFa, consistent with the immune contribution to this compound's anti-cancer properties. Finally, we demonstrated the capacity of secretome analysis to probe pathways regulating cytokine expression. For example, comparison of a set of 11 mTOR inhibitors identified on-target immune modulation and off target effects at increasing doses, enabling characterization of compound potency and specificity.Our results demonstrate the value of high-throughput proteomics to identify new immunomodulatory targets and compounds, evaluate potential toxicities, and characterize potency and specificity."

Immunomodulating • IO biomarker • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • IL1B • IL6 • TNFA

Developing zebrafish avatars for pediatric sarcomas to support functional precision oncology (AACR 2026) - "CellTiter-Glo assays at 34 °C, the incubation temperature required for zPDX experiments, confirmed that RD cells retain drug sensitivity under these conditions: dactinomycin (DAC) significantly reduced RD viability at low nanomolar concentrations (≥10 nM), whereas vincristine (VIN) was effective at 2-10 nM...Guided by media described for zPDX, we developed an enriched medium containing HEPES, glutamine, MEM-NEAA, B27, nicotinamide, ITS, Y-27632, SB202190, N-acetylcysteine, and EGF/FGF with reduced serum...Together, these preliminary data define robust survival and engraftment parameters for RMS xenografts in zebrafish, validate the feasibility of this platform for rapid chemotherapy response readouts, and establish an optimized injection medium that enables even challenging sarcoma subtypes to persist in vivo. These advances provide the foundation for extending this platform to primary pediatric sarcomas, including osteosarcoma, to generate zebrafish avatars for..."

Clinical • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • FGF

HDAC inhibitors induce NOX5 expression in human uveal melanoma cells in a Brd4-Sp1/Sp3-dependent manner (AACR 2026) - "The use of actinomycin D and cycloheximide significantly reduced HDACi-induced NOX5 expression, suggesting regulation at both transcriptional and translational levels...This process is driven by HDACi-induced histone hyperacetylation, which enhances the recruitment of BRD4, Sp1, and Sp3 to the promoter region, thereby facilitating RNA polymerase II-dependent transcription. Given that HDAC inhibition elevates both NOX5 expression and ROS production, co-targeting HDACs and NOX5 may offer a novel and effective therapeutic strategy in the treatment of UM."

Eye Cancer • Hematological Malignancies • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • BRD4 • NOX5

The combination of actinomycin D and resveratrol induces synergistic anticancer activities against aerodigestive tract cancers (AACR 2026) - "Taken together, our findings demonstrated that although the combination of Act D and resveratrol showed synergistic effects in vitro, the in vivo efficacy was not. Supported by P20GM103434 and R15DE032063."

Oncology • BBC3 • CDKN1A • GDF15

Antibody encapsulated drug: Tr-ACT2 for targeted treatments of various cancers (AACR 2026) - "Trastuzumab (Tr) has demonstrated efficacy in treatment of HER2+ breast cancer and advanced gastric cancer. Recently, Tr-based antibody drug conjugates (ADCs), Kadecyla and Enhertu, have emerged as a new class of anti-HER2 therapies by combining targeted antibodies with cytotoxic agents via linkers...Therefore, smarter and more efficient designs are urgently needed. Our patented single protein encapsulation (SPE) platform, allowing encapsulation of small-molecule drugs by a single protein (albumins or globulins) without artificial nanoparticles and chemical modifications to drugs and proteins, has achieved great success in development of 2 drug products, SPEDOX-6 under human clinical trial (NCT0764018) and SPESN38-8 (IND #: 164346) under IND-enabling study based on albumin, which have prompted us to utilize antibody, such as Tr to encapsulate cytotoxic payload, actinomycin D (ACT, RNA polymerase inhibitor), forming antibody encapsulated drugs (AEDs)... We have developed..."

Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Development of a collection of cell lines from a genetically engineered mouse model of DICER1 syndrome-associated sarcoma for therapeutic assessment (AACR 2026) - "IVADo regimen (ifosfamide/cyclophosphamide, vincristine, actinomycin-D, doxorubicin) and CDK4/6 inhibitor were selected to treat the cells...Considering that the KRAS-mutant lung cancer cells have been reported to be hypersensitive to CDK4/6 inhibitor, we tested palbociclib sensitivity and found that only one out of two Kras-mutant cell lines was sensitive to palbociclib... We validated that HDT tumors predominantly express the Dicer1IIIb-mutant transcript and most tumors were quadriphasic (epithelial, undifferentiated blastema, stromal cells, and rhabdomyoblastic cells) with no to variable amounts of anaplastic sarcoma components. From these murine HDT tumors, we have successfully derived five HDT cell lines (HDT298, HDT340, HDT366, HDT546, and HDT1003 cell lines). Some of these cell lines have aberrant p53 expression (or p53 mutation) and Kras mutation, confirming their resemblance to human DICER1-sarcoma."

Preclinical • Lung Cancer • Oncology • Sarcoma • Solid Tumor • DICER1 • KRAS • TP53

AREN0533: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor (clinicaltrials.gov) - P3 | N=395 | Active, not recruiting | Sponsor: Children's Oncology Group | Trial completion date: Mar 2026 ➔ Nov 2026

Trial completion date • Lung Cancer • Nephrology • Oncology • Renal Cell Carcinoma • Solid Tumor • Wilms Tumor

METTL3/IGF2BP2 mediates m6A methylation modification of SNRPA1 to promote tumor property of non-small cell lung cancer cells. (PubMed, Cytotechnology) - "The interaction between SNRPA1 and METTL3 or IGF2BP2 was studied using RIP assay, dual-luciferase reporter assay, and actinomycin D assay, while the association of SNRPA1 with TWIST was determined through Co-IP assay and CHX assay...The METTL3/IGF2BP2-mediated m6A methylation modification of SNRPA1 binds to TWIST1 to promote NSCLC cell proliferation, migration, and invasion, ultimately leading to NSCLC progression. The online version contains supplementary material available at 10.1007/s10616-026-00924-w."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IGF2BP2 • METTL3 • SNRPA1 • TWIST1

The PTBP1-EZH2-DOCK2 axis promotes M1 microglial polarization and exacerbates neuronal apoptosis following spinal cord injury. (PubMed, J Orthop Translat) - "In HMC3 cells, flow cytometry, IF, WB, actinomycin D treatment, RIP-qPCR, ChIP-qPCR, and dual-luciferase reporter assays were utilized to investigate the regulatory interactions among PTBP1, EZH2, and DOCK2 and their impacts on microglial polarization...This study reveals the PTBP1-EZH2-DOCK2 axis as a potential molecular basis for intervening in aberrant microglial polarization and developing novel therapeutic targets for SCI. This research possesses significant potential for clinical translation."

Journal • CNS Disorders • Infectious Disease • Inflammation • Orthopedics • EZH2 • PTBP1

Stepwise transcription stalling by the anti-cancer drug Actinomycin D and insights into short tandem repeat transcription inhibition. (PubMed, Nat Commun) - "Furthermore, we examine ACTD's effects on Pol II transcribing five disease-linked, GC-rich STRs and resolve structures of Pol II in complex with ACTD during the transcription of CTG repeats associated with myotonic dystrophy type 1. Our findings reveal the structural basis of ACTD-mediated transcription inhibition and provide a framework for the rational modification of ACTD to target STR-associated disorders."

Journal • Genetic Disorders • Muscular Dystrophy • Myotonic Dystrophy • Oncology

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial. (PubMed, Pediatr Blood Cancer) - "Survival rates following risk stratification including M + ASCT are higher than historical observations for similar high-risk groups that did not include high-dose chemotherapy."

Journal • Hematological Malignancies • Leukemia • Nephrology • Oncology • Solid Tumor • Transplantation • Wilms Tumor

Novel Pediatric Aggressive Adipose Tumor With Pathogenic TERT Promoter Variant and an Initial Durable Response to Vincristine and Dactinomycin. (PubMed, Pediatr Blood Cancer) - No abstract available

Journal • Oncology • Pediatrics

Investigation of antimicrobial synergism of actinomycin derivatives from Streptomyces parvus 35M1 against Escherichia coli ATCC 25922. (PubMed, Turk J Biol) - "Only actinomycin X2 synergized with nalidixic acid (MSAs ≥13.49 ± 2.63), while all actinomycins displayed additive/indifferent effects with rifampicin and ampicillin. This work represents the first multimodel synergy analysis of actinomycin analogs against E. coli, underscoring their potential. However, these findings are limited to in vitro assays on a single reference strain; thus, further validation with in vivo models will be necessary."

Journal • Infectious Disease

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) (clinicaltrials.gov) - P3 | N=342 | Not yet recruiting | Sponsor: Children's Oncology Group

New P3 trial • Oncology • Rhabdomyosarcoma • Sarcoma • Solid Tumor • FOXO1 • PAX3 • PAX7

Low-risk gestational trophoblastic neoplasia with primary resistance to methotrexate should be treated with multi-agent chemotherapy rather than single agent actinomycin D (Sarcoma-RC 2026) - "Legal entity responsible for the study Professor Michael Seckl. Funding Has not received any funding."

Gestational Trophoblastic Neoplasia

Analysis of 1000 secreted proteins in functional genomics and compound screens reveals cytotoxic and immunomodulatory targets (AACR-IO 2026) - "We also captured both the cytotoxic and inflammatory effects of actinomycin D, consistent with the immune contribution to this compound’s anti-cancer properties...In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr C044."

Immunomodulating • IO biomarker • Immune Modulation • Immunology • Osteosarcoma • Sarcoma • Solid Tumor • IL6

ARPC1B promotes gastric cancer tumorigenesis via IGF2BP3-mediated stabilization of HK2 mRNA and glycolytic reprogramming. (PubMed, Eur J Med Res) - "ARPC1B drives GC progression by stabilizing HK2 mRNA through IGF2BP3 binding, thereby potentiating glycolytic reprogramming to facilitate tumor growth and metastasis. Targeting the ARPC1B-IGF2BP3-HK2 axis may represent a novel therapeutic strategy for GC."

Journal • Gastric Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • ACTR2 • ARPC1B • HK2 • IGF2BP3